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Abstract
Background: Coronary heart disease (CHD) and myocardial infarction (MI) are associated with neighborhood-level
socioeconomic status (SES). Statins are important drugs for secondary prevention of MI. However, no study has
determined whether neighborhood-level SES is associated with statin medication in MI patients. We aimed to
determine whether there is a difference in statin medication rate in MI patients across different levels of
neighborhood SES.
Methods: All patients in Sweden, diagnosed with incident MI from January 1st, 2000 until December 31st 2010,
were followed (n = 116,840). Of these, 89.7 % received statin medication. Data were analyzed by multilevel logistic
regression, with individual-level characteristics (age, marital status, family income, educational attainment, country of
origin, urban/rural status and comorbidities/chronic conditions related to MI) as covariates.
Results: Low neighborhood-level SES was significantly associated with low statin medication rate (Odds Ratio 0.80).
In the full model, which took into account individual-level socioeconomic characteristics and MI comorbidities, the
odds no longer remained significant.
Conclusions: Individual-level approaches may be most important in health care policies regarding statin
medication in MI patients.
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Background
Coronary heart disease (CHD) and in particular myocardial
infarction (MI) is a major cause of morbidity, mortality and
health expense worldwide [1]. Up to 70 % of CHD inci-
dence can be explained by individual-level sociodemo-
graphic characteristics (age, sex, socioeconomic status
(SES)); health behaviors (smoking, physical inactivity, poor
diet); and metabolic risk factors (hypertension, diabetes,
hypercholesterolemia) [2]. Today, CHD prevention includes
both primary and secondary prevention with lifestyle
changes as well as medical treatment of risk factors, primar-
ily hypertension, diabetes, and hypercholesterolemia. HMG
CoA-reductase inhibitors, or statins, are a class of choles-
terol lowering drugs that are widely used in this context, in
particular for secondary prevention of MI [3]. Statins re-
duce both mortality and morbidity for CHD patients [4].
Although individual-level sociodemographic characteris-
tics, such as low individual SES, are important risk factors
for CHD incidence, recent work has also shown that low
neighborhood SES is associated with an increased risk of
CHD, after adjustment for individual SES [5–9].
However, no study has examined whether neighbor-
hood SES is associated with statin medication rates, after
taking individual socioeconomic factors into account.
Such studies are important because if there are differ-
ences in statin medication by certain neighborhood-level
characteristics, interventions will need to target such
neighborhoods.
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Sweden is a suitable setting for such a study because it
is a country which has universal health coverage for all
residents and good availability of health-related re-
sources [10]. It is therefore possible to examine whether
statin medication patterns differ, by both individual and
neighborhood level SES, in a country that has almost
equal availability of health care.
The aim of this study is to determine whether the sta-
tin medication rates for MI patients differ across neigh-
borhoods with different levels of neighborhood SES,
after taking individual factors into account.
Methods
All data were linked by the personal Swedish identifica-
tion number, which was replaced by a serial number in
the dataset in order to maintain anonymity for all indi-
viduals. Health care data were retrieved from nationwide
Swedish in-patient as well as out-patient specialist care;
the latter in order to increase the number of cases as
well as generalizability of findings. The Swedish Hospital
Discharge Register contains nationwide hospital main
and secondary discharge diagnoses encoded in the Inter-
national Classification of Diseases (ICD) format. The
tenth revision (ICD-10) has been in use since 1997 [11].
The diagnoses in the Hospital Discharge Register have a
positive predictive value between 85 and 95 %, and the
validity of many cardiovascular diseases are even higher;
e.g., MI, angina pectoris and atrial fibrillation have a
positive predictive value of > 95 % [11–13]. Since 2000,
the proportion of missing primary diagnoses has been
only 0.5–0.9 % [11].
Inclusion criteria was MI registered as the main diagno-
sis in the Hospital Discharge Register or Outpatient Regis-
ter within the study interval (2000 to 2010) using ICD-10
codes I21, I22, and I23. Only patients who previously had
no CHD were included. This was achieved by excluding
patients with a recorded main or secondary diagnosis of
CHD (ICD-10 I20-I25) during a 3-year period, i.e., from
1997 to 1999, before study start. Patients, who died be-
tween 1 January 2000 and 30 June 2005, were excluded as
medication data was not available for this time period.
Also, all patients who died within one month of MI diag-
nosis were excluded, as we assumed that some of them
might not have had a chance to pick up the medication.
Patients above 80 years of age were excluded as the pro-
portion of patients aged 80+ with statin medication was
low.
Outcome (dependent) variable
The outcome variable of medication of statins was defined
according to the ATC code C10AA for the Medication
Register.











The individual-level variables used in models were sex,
age at the start of the study, marital status, family income,
education level, country of origin, urban/rural status, and
chronic conditions related to MI (comorbidities) [14–16].
Sex: Male or female.
Age was assessed at start of follow-up. Age was used
as a continuous variable in the models.
Marital status: Individuals were classified as married/
cohabitating or widowed/divorced/never married.
Family income by quartile: Information on family in-
come in 2001 came from the Total Population Register,
provided by Statistics Sweden. Income was categorized
into quartiles: low income, middle-low income, middle-
high income, and high income. The income was divided
by the number of people in the family. A weighted sys-
tem was also used; small children were given lower
weights than adolescents since the costs of living for a
small child are lower than those for an adolescent.
Education level was classified as completion of com-
pulsory school or less (≤9 years), vocational high school
or some theoretical high school (10–12 years), and com-
pleted theoretical high school and/or college (>12 years).
Country of origin: Born in: 1) Sweden (reference), 2)
Finland, 3) Western countries, 4) Eastern European
countries, 5) Middle Eastern countries, or 6) other coun-
tries. Urban/rural status: Residence in major cities
(Stockholm, Gothenburg or Malmö), southern or north-
ern Sweden.
Chronic conditions related to MI–comorbidities were
defined as the first diagnosis (main or additional diagno-
sis) ten years before the study and during the follow-up
period of: 1) chronic lower respiratory diseases (ICD-9:
490–496; ICD-10: J40-J49), 2) alcoholism and alcohol-
related liver disease (ICD-9: 291, 303, and 571; ICD-10:
F10 and K70), 3) hypertension (ICD-9: 401–405; ICD-
10: I10-I19), and 4) diabetes mellitus (ICD-9: 250; ICD-
10: E10-E14).
Neighborhood-level socioeconomic status (SES)
The home addresses of all Swedish individuals have been
geocoded to small geographical units that have boundaries
defined by homogeneous types of buildings. These neigh-
borhood areas, developed by Statistics Sweden, are called
small areas for market statistics (SAMS) and have an
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average of 1000 people each. SAMS were used as proxies
for neighborhoods, as in previous research [7, 17]. A sum-
mary index was calculated to characterize neighborhood-
level SES [5]. The neighborhood index was based on infor-
mation on men and women aged 20–64, who lived in the
neighborhood, because people in this age group are the
most socioeconomically active. In other words, as a popula-
tion group they have a stronger impact on the socioeco-
nomic structure of the neighborhood than children,
younger men/women and retirees. The neighborhood index
was based on four items: low education level (<10 years of
formal education), low income (income from all sources,
including that from interest and dividends, defined as less
than 50 % of the median individual income), unemploy-
ment (excluding full-time students, those completing com-
pulsory military service, and early retirees) and receipt of
social welfare. The index was categorized into the following
three groups: low neighborhood SES (more than 1 SD
below the mean), middle neighborhood SES (within 1 SD
of the mean), and high neighborhood SES (more than 1 SD
above the mean) [5]. The neighborhood SES index in the
year 2000 was used in the models.
Statistical methods
Multilevel (hierarchical) logistic regression models were
used to estimate odds ratios (OR) for statin medication
rates for different levels of neighborhood SES. The ana-
lyses were performed using MLwiN version 2.27. The
first model only included neighborhood-level SES to de-
termine the crude odds of statin medication by level of
neighborhood SES (Model 1). The second model also in-
cluded the individual-level characteristics age and sex
(Model 2). The third model added family income, mari-
tal status, country of origin, educational attainment and
urban/rural status (Model 3). Last, a full model was cre-
ated which also included hospitalization due to chronic
lower respiratory disease, alcoholism and related liver
disease, type 2 diabetes mellitus or hypertension (Model
4, not shown in tables).
Random effects
The between-neighborhood variance was estimated
with a random intercept. It was regarded to be sig-
nificant if it was more than 1.96 times the size of
the standard error, in accordance with the precedent
set in previous studies [18–20].
We computed the intraclass correlation (ICC)—that is,
the intra-neighborhood correlation—in order to estimate to
what extent the individual chance of statin medication for
individuals, within the same SAMS, was similar compared
with individuals in other SAMS areas. The ICC expresses
the proportion of the total variance that is at the neighbor-
hood level. The ICC in multilevel logistic regression can be
estimated by different procedures. We applied the latent
variable method [21] as exemplified by:
ICC ¼ Vn
Vn þ π2=3
where Vn is the variance between neighborhoods and
π2/3 is the variance between individuals.
The proportion of the second level variance explained
by the different variables was calculated as:
VEXPLAINED ¼ V 0−V 1V 0  100;
where Vo is the age adjusted variance in the initial
model and V1 is the second level variance in the differ-
ent models.
First order interactions between neighborhood
deprivation and individual-level characteristics for statin
medication in MI patients were also analyzed.
For comparison, we also calculated logistic regression
models using the SAS statistical package (version 9.3;
SAS Institute, Cary, NC, USA).
Results
Table 1 shows the distribution of the study population and
number of patients receiving statins by neighborhood-level
SES. For statin medication, the number (No) of patients re-
ceiving statins as well as the share of patients on statin
medication within each patient group (%) is presented. Of
the 116,840 patients with MI included in this study,
104,766 (89.7 %) received statins during the study period.
Of the total population, 19 %, 62 %, and 19 % lived in high,
middle, and low SES neighborhoods, respectively. Age-
standardized statin medication rates was 90.6 % in neigh-
borhoods with high SES; 89.7 % in neighborhoods with
middle SES; and 88.6 % in neighborhoods with low SES.
This slight difference in statin medication rate by
neighborhood-level SES was observed across all individual-
level variables, as shown in Table 1.
Table 2 shows the age-adjusted ORs for each covariate.
Patients with low family income had significantly lower
odds of statin medication (OR 0.49) compared to pa-
tients with high family income. Low educational attain-
ment was also associated with lower odds of statin
medication (OR 0.71) compared to patients with high
educational attainment.
Table 3 shows the results of the different multilevel logis-
tic regression models. In the crude model (Model 1), the
odds of statin medication were lower for patients living in
neighborhoods with low SES. The OR for statin medication
in patients with MI living in neighborhoods with low com-
pared to high neighborhood-level SES was 0.80 (95 % confi-
dence interval (CI) 0.75–0.86). In Model 2, neighborhood-
level SES remained significantly associated with statin
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medication after adjustment for age and sex (OR 0.80, 95 %
CI 0.75–0.86).
However, in the third model, after adding individual-
level sociodemographic variables, the ORs no longer
remained significant. The fourth model also included the
variables for comorbidities, which did not change the ORs
further, and the results are therefore not shown.
The between-neighborhood variance was significant in all
models. The explained variance was 6 % in Model 1,
indicating that the neighborhood variable explained only a
small proportion of the total variance, and increased to
23 % in Model 2 and 39 % in Model 3.
The ICC was low, varying between 1.6 and 2.4 % in
the different models, indicating that the clustering
within neighborhoods was low.
Analyzing first order interactions between neighbor-
hood SES and individual-level characteristics for statin
medication in MI patients showed significant interactions
Table 1 Distribution of study population (patients with myocardial infarction, MI), number of statin medication events, and age-
standardized rates by neighborhood socioeconomic status (SES)
Population Distribution Statin medication Neighborhood SES
(%) No. % High Middle Low
Total population (%) 116,840 22,172 (19 %) 72,655 (62 %) 22,013 (19 %)
Statin medication 104,766 89.7 90.6 89.7 88.6
Sex
Men 80,351 68.8 73,223 91.1 91.8 90.6 89.0
Women 36,489 31.2 31,543 86.4 87.5 87.6 87.4
Age (years)
< 50 18,623 15.9 17,185 92.3 92.1 92.5 91.7
50–59 34,009 29.1 32,147 94.5 95.1 94.6 93.6
60–69 40,034 34.3 36,786 91.9 92.3 92.1 90.8
70–79 24,174 20.7 18,648 77.1 78.6 77.4 74.8
Educational attainment
≤ 9 55,061 47.1 47,813 86.8 89.5 88.9 87.9
10–12 31,699 27.1 29,147 91.9 91.2 91.2 89.5
> 12 30,080 25.7 27,806 92.4 92.2 91.3 89.9
Marital status
Married/cohabiting 71,108 60.9 64,923 91.3 91.6 91.4 91.0
Never married, widowed,
or divorced
45,732 39.1 39,843 87.1 88.4 87.1 85.9
Family income
Low income 29,298 25.1 25,201 86.0 88.1 87.7 87.5
Middle–low income 29,175 25.0 25,538 87.5 89.1 89.1 87.2
Middle–high income 29,202 25.0 26,812 91.8 90.8 91.0 90.5
High income 29,165 25.0 27,215 93.3 92.1 91.6 91.7
Country of origin
Sweden 99,947 85.5 89,581 89.6 90.6 89.8 88.5
Finland 5113 4.4 4568 89.3 90.4 88.2 87.0
Western countries 1379 1.2 1235 89.6 91.2 88.9 90.6
Eastern European countries 2500 2.1 2310 92.4 90.7 90.6 89.8
Middle Eastern countries 2469 2.1 2287 92.6 88.1 88.9 90.1
Others 5432 4.6 4785 88.1 89.3 88.4 86.5
Urban/rural status
Large cities 52,572 45.0 46,829 89.1 90.1 89.0 87.6
Southern Sweden 41,907 35.9 38,125 91.0 92.2 90.9 90.4
Northern Sweden 22,361 19.1 19,812 88.6 89.5 88.7 87.7
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between neighborhood level SES and education level only.
The results of this analysis are shown in Additional file 1:
Table S1.
Discussion
The present study shows that MI patients living in low
SES neighborhoods had 20 % lower odds of statin medi-
cation compared to those living in middle and high SES
neighborhoods. However, the odds no longer remained
significant after adjusting for the individual-level socio-
demographic characteristics and comorbidities. To the
best of our knowledge, the potential influence of neigh-
borhood SES on statin use in MI patients has not been
examined previously.
Previous studies have shown that statin medication
rates in CHD patients may vary due to individual-level
factors such as the patients’ age and comorbidities. In
addition, low individual-level SES may affect medication
patterns negatively [22–25] and it has been shown that
when a larger proportion of the medication costs are
required from the patients, statin utilization decreases,
in particular for less regularly compliant patients [26].
Individuals in neighborhoods with low SES are likely to
have small financial margins [27], which might affect
their willingness to pay for prescribed drugs. The find-
ings of the present study indicate that the lower odds of
statin medication in MI patients living in deprived
neighborhoods may be explained by individual-level
socioeconomic factors. This could imply that the neigh-
borhood in itself does not affect statin medication in this
patient group.
Although the present study was unable to detect a neigh-
borhood effect on statin medication in CHD patients,
previous studies have shown that neighborhood-level
deprivation is a strong predictor for CHD incidence and
fatality from CHD after adjusting for individual-level
Table 2 Odds ratios (OR) and 95 % confidence intervals (CI) for statin medication in patients with myocardial infarction; Results of
multi-level logistic regression models for each variable, adjusted for age
OR 95 % CI Variance (S.E.) Explained variance (%) Intra class correlation
Neighborhood-level Socioeconomic status (SES, ref. High) 0.068 (0.011) 22 0.020
Middle 0.93 0.88 0.98
Low 0.79 0.74 0.84
Sex (ref. Female) 1.39 1.34 1.45 0.072 (0.011) 17 0.021
Family income
(ref. High income)
0.077 (0.011) 11 0.023
Low income 0.49 0.47 0.52
Middle-low income 0.59 0.56 0.63




0.060 (0.011) 31 0.018
Never married, widowed, or divorced 0.59 0.57 0.62
Country of origin
(ref. Born in Sweden)
0.075 (0.011) 14 0.022
Finland 0.90 0.82 0.99
Western countries 1.06 0.89 1.26
Eastern European countries 1.10 0.94 1.28
Middle eastern countries 0.99 0.84 1.16
Others 0.80 0.74 0.88
Educational
attainment
(ref. > 12 years)
0.075 (0.011) 14 0.022
≤ 9 years 0.71 0.67 0.74
10–12 years 0.92 0.87 0.98
Urban/rural status
(ref. large cities)
0.059 (0.011) 32 0.018
Southern Sweden 1.28 1.22 1.34
Northern Sweden 0.98 0.93 1.03
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sociodemographic characteristics [5]. In addition, a recent
study of ours has shown that neighborhood-level
deprivation affects prescription patterns of statins in pa-
tients with atrial fibrillation, after adjusting for individual-
level factors [28]. Adults with atrial fibrillation living in high
SES neighborhoods were more often prescribed statins
(men and women, OR 1.23) compared to their counterparts
residing in middle SES neighborhoods [28]. It is unclear
why neighborhood-level deprivation affects statin medica-
tion for patients with atrial fibrillation, but not for the MI
patients in the present study.
One possible explanation could be that statin medica-
tion after MI is initiated almost exclusively at the hos-
pital, i.e., in immediate relation to the event, whereas
statin medication, for other reasons, might be initiated
at a local health care center where the potential neigh-
borhood effects may be stronger than in hospitals that
cover a wider geographic area. Previous research has
shown that prescription patterns among doctors working
in local health care centers may be affected by neighbor-
hood SES [29]. Additionally, individuals living in more
affluent neighborhoods may be better informed as pa-
tients, irrespective of individual-level SES.
Finally, differences in medication patterns may in
some cases be explained by “medication deserts”, where
pharmacies in low SES neighborhoods may have lower
availability of drugs [30]. In Sweden, with universal
health care and good availability of drugs, this is unlikely
a problem.
The results of the current study, including all MI patients
in Sweden during the study period, show that statin medi-
cation rates for these patients are generally high. Of the
116,840 patients with MI, 89.7 % received statins. For com-
parison, 89 and 88 % of patients were treated with statins
according to Italian data from the REAL registry [31] and
French data from the FAST-MI registry [32], respectively.
Table 3 Odds ratios (OR) and 95 % confidence intervals (CI) for statin medication in patients with myocardial infarction; Results of
multi-level logistic regression models
Model 1 Model 2 Model 3
OR 95 % CI OR 95 % CI OR 95 % CI
Neighborhood-level socioeconomic status (SES, ref. High)
Middle 0.90 0.86 0.95 0.94 0.89 0.99 1.07 1.01 1.13 0.016
Low 0.80 0.75 0.86 0.80 0.75 0.86 1.03 0.96 1.10 0.368
Age (years) 0.95 0.95 0.95 0.96 0.96 0.96 <0.001
Sex (ref. Female) 1.39 1.33 1.44 1.23 1.19 1.29 <0.001
Family income (ref. High income)
Low income 0.49 0.46 0.52 <0.001
Middle-low income 0.62 0.58 0.65 <0.001
Milddle-high income 0.83 0.78 0.89 <0.001
Marital status (ref. Married/co-habiting)
Never married, widowed, or divorced 0.61 0.58 0.63 <0.001
Country of origin (ref. Born in Sweden)
Finland 1.02 0.93 1.12 0.689
Western countries 1.07 0.89 1.27 0.484
Eastern European countries 1.33 1.14 1.55 <0.001
Middle eastern countries 1.33 1.13 1.56 <0.001
Others 0.92 0.84 1.00 0.046
Educational attainment (ref. > 12 years)
≤ 9 years 0.89 0.84 0.94 <0.001
10–12 years 1.13 1.06 1.21 <0.001
Urban/rural status (ref. large cities)
Southern Sweden 1.30 1.24 1.37 <0.001
Northern Sweden 1.02 0.97 1.08 0.424
Variance (S.E.) 0.082 (0.011) 0.067 (0.011) 0.053 (0.011)
Explained variance (%) 6 23 39
Intra class correlation 0.024 0.020 0.016
Model 1. Crude model; Model 2: Adjusted for age and sex; Model 3: Adjusted for age, sex, and individual socioeconomic variables
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In the US, several studies of statin medication for CHD
patients have shown medication rates of about 60-70 %
[33–35]. However, those studies only included a sub-set of
MI patients, and the authors of one of the studies that re-
ported high medication rates explained their findings as a
result of only including highly motivated medical practices
[36]. It has previously been shown that in countries without
universal health insurance, lack of individual health insur-
ance is associated with lower likelihood of being treated
with a statin [35, 36]. It is also possible that availability of
generic statins will result in lower costs for the patients and
improved compliance. The high statin medication rates in
this study indicates that universal health care may improve
statin medication for MI patients, which could be an argu-
ment in support of providing universal health care to the
entire population.
Limitations and strengths
Our study has some limitations. Residual confounding
may exist as socioeconomic measures only represent
proxies for individual-level status. However, as the lower
odds of statin medication in those MI patients living in
deprived neighborhoods no longer remained significant
after the statistical adjustments, it is likely that our so-
cioeconomic measures are relatively good proxies of
individual-level socioeconomic status. Another limita-
tion is that we did not account for mobility, i.e., move to
a different neighborhood during the follow-up period.
However, we have previously checked the mobility in
this age group and found it to be low. In addition, the
follow-up period was relatively short, which implies that
most people likely remained in their neighborhood dur-
ing the study period.
This study has also, however, several strengths. The
large cohort, which included practically all patients diag-
nosed with MI in Sweden during the study period, in-
creases the generalizability of our results as very little
data is missing. Another strength is the use of personal
identification numbers, which made it possible to link
health care data to socioeconomic data as well as follow-
ing individuals in different national registers. A further
strength is the use of the Hospital Discharge Register,
which has high validity, especially for cardiovascular dis-
orders [11–13]. Finally, the use of multilevel modeling
helped us to separate neighborhood-level and individual-
level effects and allowed for consideration of both ran-
dom and fixed effects.
Conclusion
Neighborhood-level SES was modestly associated with
statin medication rates in MI patients and this associ-
ation was no longer significant after adjusting for
individual-level sociodemographic factors. These find-
ings raise important clinical and public health concerns,
and indicate that individual-level approaches may be
most important in health care policies regarding statin
medication in MI patients.
Highlight
 This is the first study to determine whether
neighborhood socioeconomic status is associated
with statin medication rates in myocardial infarction
(MI) patients.
 Low neighborhood-level socioeconomic status was
significantly associated with lower statin medication
rates (odds ratio 0.80).
 After adjustment for individual-level socioeconomic
characteristics and comorbidities, this association
was no longer significant.
 Individual-level approaches may be most important
in health care policies regarding statin medication in
MI patients.
Additional file
Additional file 1: Table S1. Evaluating the interaction between
neighborhood deprivation and individual-level characteristics for statin
medication in myocardial infarction patients. (DOCX 31 kb)
Abbreviations
CHD, Coronary heart disease; ICC, intraclass correlation; ICD, International
Classification of Diseases; MI, myocardial infarction; OR, Odds ratio; SES,
socioeconomic status
Acknowledgements
This work was supported by the Swedish Research Council to Kristina
Sundquist and the National Heart, Lung, And Blood Institute of the National
Institutes of Health under Award Number R01HL116381 to Kristina Sundquist.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
Funding
The funding sources had no role in the design, conduct, or analysis of the
study or in the decision to submit the manuscript for publication.
Availability of data and materials
The dataset used in the present study was retrieved from nationwide
registers provided by the National Board of Health and Welfare (health care
data) and Statistics Sweden, the Swedish Government-owned statistics bur-
eau (population data).
Authors’ contributions
All authors contributed to the conception and design of the study; KS
contributed to the acquisition of data; XL contributed to the analysis and
interpretation of data; POF drafted the manuscript; and all authors revised it
critically and approved the final version. All authors had full access to all of
the data (including statistical reports and tables) and take responsibility for
the integrity of the data and the accuracy of their analysis.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Forsberg et al. BMC Cardiovascular Disorders  (2016) 16:146 Page 7 of 8
Ethics approval and consent to participate
This study was approved by the Ethics Committee of Lund University,
Sweden, and was conducted in accordance with the 1975 Declaration of
Helsinki. No individual consent was needed as this study was based on
secondary data from nationwide registers.
Received: 24 March 2016 Accepted: 8 June 2016
References
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.
Heart disease and stroke statistics–2015 update: a report from the American
Heart Association. Circulation. 2015;131:e29–322.
2. Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT. Do
cardiovascular risk factors explain the relation between socioeconomic
status, risk of all-cause mortality, cardiovascular mortality, and acute
myocardial infarction? Am J Epidemiol. 1996;144:934–42.
3. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et
al. Statins for the primary prevention of cardiovascular disease. Cochrane
Database Syst Rev. 2013;1:Cd004816.
4. Group Scandinavian Simvastatin Survival Study. Randomised trial of
cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
5. Winkleby M, Sundquist K, Cubbin C. Inequities in CHD incidence and case
fatality by neighborhood deprivation. Am J Prev Med. 2007;32:97–106.
6. Sundquist K, Winkleby M, Ahlen H, Johansson SE. Neighborhood
socioeconomic environment and incidence of coronary heart disease: a
follow-up study of 25,319 women and men in Sweden. Am J Epidemiol.
2004;159:655–62.
7. Cubbin C, Sundquist K, Ahlen H, Johansson SE, Winkleby MA, Sundquist J.
Neighborhood deprivation and cardiovascular disease risk factors: protective
and harmful effects. Scand J Public Health. 2006;34:228–37.
8. Sundquist K, Malmstrom M, Johansson SE. Neighbourhood deprivation and
incidence of coronary heart disease: a multilevel study of 2.6 million
women and men in Sweden. J Epidemiol Community Health. 2004;58:71–7.
9. Sundquist K, Li X. Coronary heart disease risks in first- and second-
generation immigrants in Sweden: a follow-up study. J Intern Med. 2006;
259:418–27.
10. Kawakami N, Winkleby M, Skog L, Szulkin R, Sundquist K. Differences in
neighborhood accessibility to health-related resources: a nationwide
comparison between deprived and affluent neighborhoods in Sweden.
Health Place. 2011;17:132–9.
11. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et
al. External review and validation of the Swedish national inpatient register.
BMC Public Health. 2011;11:450.
12. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of
heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787–91.
13. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B. Reliability of the
hospital registry. The diagnostic data are better than their reputation.
Lakartidningen. 1994;91(598):603–5.
14. Zöller B, Li X, Sundquist J, Sundquist K. Neighborhood deprivation and
hospitalization for venous thromboembolism in Sweden. J Thromb
Thrombolysis. 2012;34:374–82.
15. Zöller B, Li X, Sundquist J, Sundquist K. Neighbourhood deprivation and
hospitalization for atrial fibrillation in Sweden. Europace. 2013;15:1119–27.
16. Li X, Sjöstedt C, Sundquist K, Zöller B, Sundquist J. Neighborhood
deprivation and childhood autism: a nationwide study from Sweden. J
Psychiatr Res. 2014;53:187–92.
17. Sundquist J, Johansson SE, Yang M, Sundquist K. Low linking social capital
as a predictor of coronary heart disease in Sweden: a cohort study of 2.8
million people. Soc Sci Med. 2006;62:954–63.
18. Johnell K, Lindstrom M, Melander A, Sundquist J, Eriksson C, Merlo J.
Anxiolytic-hypnotic drug use associated with trust, social participation, and
the miniaturization of community: a multilevel analysis. Soc Sci Med.
2006;62:1205–14.
19. Johnell K, Lindstrom M, Sundquist J, Eriksson C, Merlo J. Individual
characteristics, area social participation, and primary non-concordance with
medication: a multilevel analysis. BMC Public Health. 2006;6:52.
20. Sundquist K, Theobald H, Yang M, Li X, Johansson SE, Sundquist J.
Neighborhood violent crime and unemployment increase the risk of
coronary heart disease: A multilevel study in an urban setting. Soc Sci Med.
2006;62:2061–71.
21. Snijders PTABB, Bosker TABSRJ, Bosker PRJ. Multilevel analysis: an
introduction to basic and advanced multilevel modeling: SAGE. 1999.
22. Brooks JM, Cook EA, Chapman CG, Kulchaitanaroaj P, Chrischilles EA, Welch S, et
al. Geographic variation in statin use for complex acute myocardial infarction
patients: evidence of effective care? Med Care. 2014;52 Suppl 3:S37–44.
23. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention
of coronary heart disease: is treatment equitable? Heart. 2002;88:15–9.
24. Headen Jr AE, Masia NA, Axelsen KJ. Effects of medicaid access restrictions
on statin utilisation for patients treated by physicians practising in poor and
minority neighbourhoods. PharmacoEconomics. 2006;24 Suppl 3:41–53.
25. Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Alla F, Danchin
N, et al. Frequency of cardiovascular diseases and risk factors treated in
France according to social deprivation and residence in an overseas
territory. Int J Cardiol. 2014;173:430–5.
26. Thiebaud P, Patel BV, Nichol MB. The demand for statin: the effect of copay
on utilization and compliance. Health Econ. 2008;17:83–97.
27. Carlsson A, Starrin B, Gigante B, Leander K, Hellenius M-L, de Faire U.
Financial stress in late adulthood and diverse risks of incident cardiovascular
disease and all-cause mortality in women and men. BMC Public Health.
2014;14:17.
28. Carlsson AC, Wändell P, Gasevic D, Sundquist J, Sundquist K. Neighborhood
deprivation and warfarin, aspirin and statin prescription - A cohort study of
men and women treated for atrial fibrillation in Swedish primary care. Int J
Cardiol. 2015;187:547–52.
29. Pimenta E, Stowasser M. Uncontrolled hypertension: beyond
pharmacological treatment. Hypertens Res. 2009;32:729–31.
30. Amstislavski P, Matthews A, Sheffield S, Maroko A, Weedon J. Medication
deserts: survey of neighborhood disparities in availability of prescription
medications. Int J Health Geogr. 2012;11:48.
31. Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L, et al.
Impact of COPD on long-term outcome after ST-segment elevation
myocardial infarction receiving primary percutaneous coronary intervention.
Chest. 2013;144:750–7.
32. Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, et al.
French registry on acute ST-elevation and non ST-elevation myocardial
infarction 2010. FAST-MI 2010. Heart. 2012;98:699–705.
33. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR. Cardiovascular risk
and statin use in the United States. Ann Fam Med. 2014;12:215–23.
34. Goff DC, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Quality of care for
secondary prevention for patients with coronary heart disease: results of the
Hastening the Effective Application of Research through Technology
(HEART) trial. Am Heart J. 2003;146:1045–51.
35. Johansen ME, Hefner JL, Foraker RE. Antiplatelet and statin use in US
patients with coronary artery disease categorized by race/ethnicity and
gender, 2003 to 2012. Am J Cardiol. 2015;115:1507–12.
36. Arnold SV, Spertus JA, Tang F, Krumholz HM, Borden WB, Farmer SA, et al.
Statin use in outpatients with obstructive coronary artery disease.
Circulation. 2011;124:2405–10.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Forsberg et al. BMC Cardiovascular Disorders  (2016) 16:146 Page 8 of 8
